FOLR1 and ovarian carcinoma: We next attempted to correlate expression levels of PODO447 immunoreactivity with other well-characterized ovarian tumor markers including CA125 (a mucin 16 epitope), mesothelin (MSLN) and folate receptor alpha (FOLRA), three tumor antigens expressed by HGSOC that are under development as therapeutic targets for the treatment of ovarian cancer (30–36).